Lumen lands another DoD contract to treat Covid-related GI issues
The team at Lumen Bioscience believes that it can help patients, including those infected with Covid-19, through its plant-based drug LMN-301. Wednesday, it announced that the US Army is a believer too, handing the company development funding for its monoclonal antibody cocktail.
This deal builds on a previous grant from the US Army that helped fund preclinical development of the candidate to treat and prevent the gastrointestinal symptoms of Covid-19, which often takes a back seat to the concerns surrounding respiratory issues. A study out of Wuhan found that GI symptoms were found in 85% of severely ill Covid-19 patients, and 79% in stable patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
